Vogenx (NASDAQ:VOGX) Upgraded at JonesTrading
by Michael Walen · The Markets DailyVogenx (NASDAQ:VOGX – Get Free Report) was upgraded by JonesTrading to a “strong-buy” rating in a note issued to investors on Monday, Zacks reports.
Separately, Wall Street Zen upgraded Vogenx to a “hold” rating in a research note on Saturday, August 22nd. One research analyst has rated the stock with a Strong Buy rating, Based on data from MarketBeat.com, Vogenx presently has an average rating of “Strong Buy” and an average target price of $55.00.
Check Out Our Latest Report on VOGX
Vogenx Stock Performance
NASDAQ:VOGX opened at $33.13 on Monday. Vogenx has a 1-year low of $12.95 and a 1-year high of $35.50.
About Vogenx
Vogenx Inc is a clinical-stage biopharmaceutical company. It focused on the discovery and development of novel therapeutics for the treatment of serious diseases associated with dysfunctions in human metabolism, including PBH and gastroparesis. The company’s product candidate includes mizagliflozin, is an orally administered, minimally absorbed small molecule drug candidate in development for the treatment of PBH, gastroparesis, and GIP-dependent Cushing’s Syndrome. Vogenx Inc is based in RALEIGH, NC.